Inventor · disambiguated record
Paul Parren
Also filed as: PARREN PAUL · PARREN PAUL W H I · PARREN PAUL WILLEM HENRI IDA · PARREN PAUL WILLEM HENRI LDA
130 granted patents·116 pending applications·1,598 citations·filing 2003–2025
99Inventor score
Top patents by PatentIndex Score
246 records- 0198US11542323B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Jan 3, 2023·6 cites·24 claims
- 0298US11524995B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Dec 13, 2022·6 cites·20 claims
- 0398US11485796B2Inert formatGENMAB AS·Filed 2020·Granted Nov 1, 2022·6 cites·20 claims
- 0498US11440966B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 13, 2022·12 cites·21 claims
- 0598US11084882B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2020·Granted Aug 10, 2021·8 cites·11 claims
- 0698US7829673B2Antibodies against CD38 for treatment of multiple myelomaGENMAB AS·Filed 2006·Granted Nov 9, 2010·148 cites·29 claims
- 0797US12049512B2Antibody variants and uses thereofGENMAB BV·Filed 2020·Granted Jul 30, 2024·5 cites·17 claims
- 0897US11866514B2Heterodimeric antibody Fc-containing proteins and methods for production thereofGENMAB AS·Filed 2020·Granted Jan 9, 2024·5 cites·37 claims
- 0997US11421024B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Aug 23, 2022·6 cites·23 claims
- 1097US10800836B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2016·Granted Oct 13, 2020·10 cites·10 claims
- 1197US10647764B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 1297US10647763B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 1397US10640554B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 5, 2020·9 cites·14 claims
- 1497US10597464B2Heterodimeric antibody Fc-containing proteins and methods for production thereofGENMAB AS·Filed 2017·Granted Mar 24, 2020·35 cites·12 claims
- 1597US9150663B2Heterodimeric antibody Fc-containing proteins and methods for production thereofLABRIJN ARAN FRANK·Filed 2011·Granted Oct 6, 2015·119 cites·37 claims
- 1697US7563441B2Anti-P-selectin antibodiesHOFFMANN LA ROCHE·Filed 2005·Granted Jul 21, 2009·94 cites·34 claims
- 1797US7501496B1Anti-OX40L antibodiesROCHE PALO ALTO LLC·Filed 2005·Granted Mar 10, 2009·87 cites·26 claims
- 1896US11091557B2Methods of producing multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2017·Granted Aug 17, 2021·10 cites·20 claims
- 1996US10590206B2Inert formatGENMAB AS·Filed 2014·Granted Mar 17, 2020·29 cites·20 claims
- 2096US10364285B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 30, 2019·13 cites·9 claims
- 2196US10358484B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 2296US10358483B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 2395US12077596B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 3, 2024·2 cites·20 claims
- 2495US11939388B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Mar 26, 2024·2 cites·13 claims
- 2595US11396553B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Jul 26, 2022·8 cites·23 claims
- 2695US10906991B2Bispecific antibodies and methods for production thereofGENMAB AS·Filed 2015·Granted Feb 2, 2021·15 cites·6 claims
- 2795US10358482B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·11 cites·9 claims
- 2895US10344050B2Production of heterodimeric proteinsGENMAB AS·Filed 2012·Granted Jul 9, 2019·40 cites·52 claims
- 2995US9593164B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2013·Granted Mar 14, 2017·34 cites·2 claims
- 3094US11512137B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Nov 29, 2022·10 cites·10 claims
- 3194US11034772B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Jun 15, 2021·7 cites·20 claims
- 3294US10407501B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2015·Granted Sep 10, 2019·15 cites·19 claims
- 3394US9212230B2Bispecific antibodies and methods for production thereofSCHUURMAN JANINE·Filed 2008·Granted Dec 15, 2015·54 cites·29 claims
- 3494US9040050B2Combination treatment of CD38-expressing tumorsVAN DE WINKEL JAN·Filed 2007·Granted May 26, 2015·39 cites·68 claims
- 3594US7438907B2Human monoclonal antibodies against CD25GENMAB AS·Filed 2003·Granted Oct 21, 2008·50 cites·31 claims
- 3693US11492371B2Production of heterodimeric proteinsGENMAB AS·Filed 2019·Granted Nov 8, 2022·9 cites·21 claims
- 3793US10759867B2Antibody variants and uses thereofPARREN PAUL·Filed 2012·Granted Sep 1, 2020·14 cites·6 claims
- 3893US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 3993US9944711B2Antibodies against human CD38GENMAB AS·Filed 2016·Granted Apr 17, 2018·16 cites·48 claims
- 4093US9580508B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2014·Granted Feb 28, 2017·19 cites·22 claims
- 4193US9492565B2Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2015·Granted Nov 15, 2016·7 cites·16 claims
- 4293US7868141B2Anti-OX40L antibodiesROCHE PALO ALTO LLC·Filed 2008·Granted Jan 11, 2011·21 cites·23 claims
- 4393US7282568B2Human monoclonal antibodies against interleukin 8 (IL-8)GENMAB AS·Filed 2003·Granted Oct 16, 2007·39 cites·23 claims
- 4492US11613575B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2019·Granted Mar 28, 2023·4 cites·18 claims
- 4592US11359015B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2016·Granted Jun 14, 2022·6 cites·24 claims
- 4692US11339215B2Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8)CORMORANT PHARMACEUTICALS AB·Filed 2019·Granted May 24, 2022·4 cites·19 claims
- 4792US10479835B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Nov 19, 2019·4 cites·16 claims
- 4892US10428147B2Anti-sortilin antibodies, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Oct 1, 2019·4 cites·7 claims
- 4992US9657107B2Monoclonal antibodies against c-MetGENMAB AS·Filed 2015·Granted May 23, 2017·9 cites·25 claims
- 5092US9168314B2Human antibody drug conjugates against tissue factorSATIJN DAVID·Filed 2011·Granted Oct 27, 2015·29 cites·11 claims
Showing the top 50 of 246 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Paul Parren files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →